Maintenance olaparib (Lynparza) plus bevacizumab (Avastin) following first-line standard-of-care treatment improved overall survival (OS) in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency (HRD), according to final OS results from the phase 3 PAOLA-1/ENGOT-ov25 … trial presented at the 2022 ESMO Congress.
This is an edited version of an article written by Kristie L. Kahl and published in OncLive Sept. 9, 2022
Maintenance therapy with niraparib (Zejula) significantly improved progression-free survival (PFS) compared with placebo in Chinese patients with newly diagnosed advanced ovarian cancer who achieved a complete response (CR) or partial response (PR) to first-line chemotherapy, according to data from the phase 3 PRIME trial (NCT03709316).1
This is an edited version of an article written by Chris Ryan and published in OncLive July 26, 2022
Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options. However, a new option for these patients whose disease harbors a high level of folate receptor α (FRα) may be emerging as the first-in-class antibody-drug conjugate mirvetuximab soravtansine displayed promising antitumor activity, according to results from the phase 3 SORAYA trial (NCT04296890) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. …
This is an edited version of an article by Kyle Doherty appearing in OncLive, July 2, 2022.
The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer, according to data from the dose-expansion portion of the phase 1 Study 101 trial (NCT03386942) presented during the 2022 ASCO Annual Meeting.
This is an edited version of an article by Chris Ryan published 21 June 2022 by The Clearity Foundation
University of Queensland researchers have demonstrated a genetic link between endometriosis and ovarian cancer subtypes enabling them to identify potential drug targets for therapy and increasing the understanding of both diseases.
This article is taken from ScienceDaily, March 15, 2022
If you are having issues printing the applications or have questions on how to fill them out and submit them, complete this form and someone will get back to you soon.
Fill out this form to receive an email reminder when the retreat applications are available.
